BRAF and RAP1A

Data Source:
BioGRID (affinity chromatography technology)
HPRD (in vivo)

		BRAF	RAP1A
Description		B-Raf proto-oncogene, serine/threonine kinase	RAP1A, member of RAS oncogene family
Image
GO Annotations	Cellular Component	Nucleus Cytosol Plasma Membrane Intracellular Membrane-bounded Organelle	Cytoplasm Early Endosome Late Endosome Cytosol Plasma Membrane Cell Junction Guanyl-nucleotide Exchange Factor Complex Specific Granule Membrane Neuron Projection Phagocytic Vesicle Perinuclear Region Of Cytoplasm Extracellular Exosome Glutamatergic Synapse
	Molecular Function	Protein Kinase Activity Protein Serine/threonine Kinase Activity Calcium Ion Binding Protein Binding ATP Binding Small GTPase Binding Identical Protein Binding Scaffold Protein Binding Protein Serine Kinase Activity Protein Threonine Kinase Activity	GTPase Activity Guanyl-nucleotide Exchange Factor Activity Protein Binding GTP Binding GDP Binding Small GTPase Binding Protein-containing Complex Binding
	Biological Process	MAPK Cascade Activation Of MAPKK Activity Protein Phosphorylation Epidermal Growth Factor Receptor Signaling Pathway Animal Organ Morphogenesis Positive Regulation Of Gene Expression Positive Regulation Of Glucose Transmembrane Transport Positive Regulation Of Peptidyl-serine Phosphorylation Negative Regulation Of Apoptotic Process Positive Regulation Of ERK1 And ERK2 Cascade Trehalose Metabolism In Response To Stress Cellular Response To Calcium Ion Establishment Of Protein Localization To Membrane	Nervous System Development Response To Carbohydrate Positive Regulation Of Neuron Projection Development Microvillus Assembly Rap Protein Signal Transduction Negative Regulation Of Collagen Biosynthetic Process Cellular Response To Drug Nerve Growth Factor Signaling Pathway Neutrophil Degranulation Positive Regulation Of GTPase Activity Positive Regulation Of Protein Kinase Activity Positive Regulation Of Glucose Import Regulation Of Insulin Secretion Establishment Of Endothelial Barrier Positive Regulation Of ERK1 And ERK2 Cascade Cellular Response To CAMP Protein Localization To Plasma Membrane Response To Antineoplastic Agent Liver Regeneration Regulation Of Neurotransmitter Receptor Localization To Postsynaptic Specialization Membrane Regulation Of Cell Junction Assembly Positive Regulation Of Fc-gamma Receptor Signaling Pathway Involved In Phagocytosis Cellular Response To Nerve Growth Factor Stimulus Negative Regulation Of Synaptic Vesicle Exocytosis Positive Regulation Of Vasculogenesis
Pathways		Spry regulation of FGF signaling Frs2-mediated activation Frs2-mediated activation ARMS-mediated activation Signalling to p38 via RIT and RIN RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by MRAS-complex mutants	Frs2-mediated activation Frs2-mediated activation ARMS-mediated activation ARMS-mediated activation Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins Glucagon-like Peptide-1 (GLP1) regulates insulin secretion Rap1 signalling MAP2K and MAPK activation Neutrophil degranulation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF MET activates RAP1 and RAC1 Signaling downstream of RAS mutants Signaling by RAF1 mutants
Drugs		Sorafenib XL281 RAF-265 PLX-4720 N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime Vemurafenib Regorafenib Dabrafenib Encorafenib Fostamatinib Ripretinib
Diseases		Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Thyroid cancer Malignant melanoma
GWAS		anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy) ( 31835028) Bipolar disorder ( 31043756) Cerebrospinal fluid t-tau:AB1-42 ratio ( 26252872) Cerebrospinal T-tau levels ( 26252872) Mild influenza (H1N1) infection ( 26379185) Response to Vitamin E supplementation ( 22437554) Type 2 diabetes ( 32499647 28869590)	Cognitive ability, years of educational attainment or schizophrenia (pleiotropy) ( 31374203) Crohn's disease ( 30500874 32581322) High altitude adaptation ( 28373541) Lymphocyte counts ( 32888494) Monocyte count ( 32888494) Osteoporosis-related phenotypes ( 20548944)
Interacting Genes		46 interacting genes: AKT1 ARAF AURKA BAD CCDC88A CTSV FBP1 HRAS HSD17B3 ITCH KRAS LATS2 MAP2K1 MAP2K2 MAP2K3 MAP2K6 MAPK1 MAPK3 MRAS NANOG OIP5 PAK2 PEBP1 PPP2CA PPP2R2A PRKACA PRKCE RAF1 RAP1A RAP1GAP RASSF1 RHEB SFN SGK1 SPRY2 STK11 TERF1 TERT UBE2L3 YWHAB YWHAG YWHAH YWHAQ YWHAZ ZNF189 ZNF510	43 interacting genes: AFDN APBB1IP ARHGEF1 BIN1 BMX BRAF ELOA FADD FAF1 FAS GABARAPL2 GANAB HDAC1 HSPA1A HSPA4 KRIT1 MTNR1A NTRK1 PDE6D PPP2R1A PRKACA RABAC1 RAF1 RALGDS RAP1GAP RAP1GDS1 RAPGEF1 RAPGEF2 RAPGEF3 RAPGEF4 RAPGEF5 RAPGEF6 RASA1 RASA3 RASGRP2 RASGRP4 RASIP1 RGL4 RGS14 RUNDC3A SMARCA2 SMARCA4 TNFRSF10C
Entrez ID		673	5906
HPRD ID		01264	01545
Ensembl ID		ENSG00000157764	ENSG00000116473
Uniprot IDs		P15056	A8KAH9 P62834
PDB IDs		1UWH 1UWJ 2FB8 2L05 3C4C 3D4Q 3IDP 3II5 3NY5 3OG7 3PPJ 3PPK 3PRF 3PRI 3PSB 3PSD 3Q4C 3Q96 3SKC 3TV4 3TV6 4CQE 4DBN 4E26 4E4X 4EHE 4EHG 4FC0 4FK3 4G9C 4G9R 4H58 4JVG 4KSP 4KSQ 4MBJ 4MNE 4MNF 4PP7 4R5Y 4RZV 4RZW 4WO5 4XV1 4XV2 4XV3 4XV9 4YHT 5C9C 5CSW 5CSX 5CT7 5FD2 5HI2 5HID 5HIE 5ITA 5J17 5J18 5J2R 5JRQ 5JSM 5JT2 5VAL 5VAM 5VR3 5VYK 6B8U 6CAD 6N0P 6N0Q 6NSQ 6NYB 6P3D 6P7G 6PP9 6Q0J 6Q0K 6Q0T 6U2G 6U2H 6UAN 6UUO 6XAG	1C1Y 1GUA 3KUC 4KVG
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?